Immutep Ltd Stock News

Immutep Limited (NASDAQ:IMMP) concluded the trading at $3.09 on Friday, December 03 with a fall of -8.04% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.36 and 5Y monthly beta was reading 1.45 with its price kept floating in the range Immutep Limited (IMMP) Offers An Excellent Investment Opportunity At Current Levels Read More »

Geode Capital Management LLC acquired a new stake in shares of Immutep Limited (NASDAQ:IMMP) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,131 shares of the biotechnology companys stock, valued at approximately $46,000. Other large investors have also recently modified their holdings []

Marshall Wace LLP acquired a new position in Immutep Limited (NASDAQ:IMMP) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 165,768 shares of the biotechnology companys stock, valued at approximately $642,000. Other hedge funds and other institutional investors have also added to or reduced their []

Millennium Management LLC boosted its holdings in Immutep Limited (NASDAQ:IMMP) by 563.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,403,441 shares of the biotechnology companys stock after purchasing an additional 1,191,972 shares during the quarter. Millennium Management LLC []

SYDNEY, AUSTRALIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the last patient has been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study (also designated KEYNOTE-798). The Company announced that the TACTI-002 study has completed recruitment of patients across all cohorts.

Immutep Limited (NASDAQ:IMMP) saw a significant growth in short interest in the month of October. As of October 29th, there was short interest totalling 101,400 shares, a growth of 83.0% from the October 14th total of 55,400 shares. Based on an average daily volume of 318,800 shares, the short-interest ratio is presently 0.3 days. A []

SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new data has been published in poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 which took place from 10-14 November 2021 in the US. The new data relates to the Companys Phase IIb AIPAC trial and Part C of its Phase II TACTI-002 study (also designated KEYNOTE-798). In addition, a poster presentation of the trial design of the Companys new randomised Phase IIb study in 1st line HNSCC was also presented at SITC.

SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL 201680005401.3) entitled Combined Preparations for the Treatment of Cancer or Infection by the Chinese Patent Office.

Immutep Limited (NASDAQ: IMMP) has announced final overall survival data (OS) from its Phase 2b AIPAC trial. 227 patients with HER2-negative/HR-positive metastatic breast cancer (HR+ MBC) were 1:1

SYDNEY, AUSTRALIA, Nov. 10, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy

SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherap

SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy

Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 1 September 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing no

Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partne

Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of pate